RE-LuPSMA trial: what clinicians have said so far
Re-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPSMA Trial
- NCT06288113 ↗
- Recruiting
- Jonsson Comprehensive Cancer Center
- Focused size, estimated: 1–150 verified statements once built
Discussed at: ESMO Congress 2026
We haven't built an HCP commentary report on RE-LuPSMA (lutetium lu 177 vipivotide tetraxetan in metastatic castration-resistant prostate cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on RE-LuPSMA so far
Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 5 posts on X, typically up to 22 once built | |
| 2 YouTube videos, typically up to 9 once built |
The trial
ClinicalTrials.gov- Official title
- Re-Treatment With 177Lu-PSMA-617 Molecular Radiotherapy for Metastatic Castration Resistant Prostate Cancer: A Prospective Phase 2 Trial (RE-LuPSMA STUDY)
- Phase
- Phase 2
- Status
- Recruiting
- Conditions
- Castration-Resistant Prostate Carcinoma; Stage IVB Prostate Cancer AJCC v8
- Interventions
- Biospecimen Collection; Computed Tomography; Gallium Ga 68 Gozetotide; Lutetium Lu 177 Vipivotide Tetraxetan; Positron Emission Tomography; Questionnaire Administration; Single Photon Emission Computed Tomography
- Arms
- Treatment (177Lu-PSMA-617) · Experimental
- Enrollment
- 40 (estimated)
- Primary outcomes
- 12-month overall survival
- Sponsor
- Jonsson Comprehensive Cancer Center with Novartis Pharmaceuticals
- Start
- Aug 1, 2024
- Primary completion
- Jan 27, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT06288113 · updated Mar 13, 2026
Publications
linked from the registry- Nikitas J, Holzgreve A, Juarez J, Kimura K, Lira S, Alam H, Contreras M, Theus L, Nguyen AT, Ells Z, Zhu S, Grogan T, Elashoff DA, Unterrainer LM, Dahlbom M, Allen-Auerbach M, Czernin J, Calais J. Phase 2 Prospective Trial of Retreatment with [177Lu]Lu-PSMA-617 Molecular Radiotherapy for Metastatic Castration-Resistant Prostate Cancer-RE-LuPSMA. J Nucl Med. 2026 May 1;67(5):674-680. doi: 10.2967/jnumed.125.271231. PubMed 41679923